Form 4: Dyne Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Susanna Gatti High, Chief Operating Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.
Summary
- On May 16, 2024, Susanna Gatti High, the Chief Operating Officer of Dyne Therapeutics, sold 2,249 shares of common stock at a weighted average price of $28.20.
- She also sold 489 shares at a weighted average price of $28.59.
- These sales were to cover tax withholding obligations related to the vesting of restricted stock units granted on November 15, 2023.
- The sales were executed under a pre-arranged plan (Rule 10b5-1) established on January 25, 2024.
- Following these transactions, High still beneficially owns 154,062 shares, including 139,899 unvested RSUs.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction (share sales for tax obligations) and doesn't indicate any significant positive or negative sentiment.
Industry Context
Executive share sales for tax purposes are a common occurrence, especially after vesting of restricted stock units.
Stakeholder Impact
- The share sales by an executive could have a minor impact on shareholder sentiment, but the reason for the sale (tax obligations) is generally understood.
Key Dates
| Date | Description |
|---|---|
| 2023-11-15 | Date of restricted stock units grant |
| 2024-01-25 | Date of Rule 10b5-1 plan establishment |
| 2024-05-16 | Date of share sale transaction |
| 2024-05-17 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.